Roche Glycart is a biotechnology company, engages in the research, development, and commercialization of antibody-based products.
Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.